Loris Riccardo Lopetuso

List of Publications by Year in Descending Order

88 papers	3,406 citations	30 h-index	57 g-index
98 ext. papers	4,764 ext. citations	4.1 avg, IF	5.49 L-index

#	Paper	IF	Citations
88	Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. *Gastroenterology Nursing*, **2021**, 44, E59-E66	1	1
87	Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia. *Inflammatory Bowel Diseases*, **2021**, 27, 902-913	4.5	3
86	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 205-206	6.9	
85	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211006669	4.7	7
84	Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients. *Gastroenterology*, **2021**, 161, 368-369	13.3	2
83	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. *International Journal of Clinical Practice*, **2021**, 75, e14755	2.9	5
82	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.. *Expert Opinion on Biological Therapy*, **2021**, 1-8	5.4	
81	Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. *European Review for Medical and Pharmacological Sciences*, **2021**, 25, 5826-5835	2.9	
80	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820968747	4.7	1
79	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. *PLoS ONE*, **2020**, 15, e0231789	3.7	28
78	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. *Digestive and Liver Disease*, **2020**, 52, 1002-1010	3.3	10
77	Fecal transplantation for ulcerative colitis: current evidence and future applications. *Expert Opinion on Biological Therapy*, **2020**, 20, 343-351	5.4	20
76	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. *Liver International*, **2020**, 40, 878-888	7.9	32
75	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. *United European Gastroenterology Journal*, **2020**, 8, 775-781	5.3	23
74	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. *Digestive and Liver Disease*, **2020**, 52, 1390-1395	3.3	8
73	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. *Endoscopy International Open*, **2020**, 8, E980-E984	3	3
72	Assessment of neurological manifestations in hospitalized patients with COVID-19. *European Journal of Neurology*, **2020**, 27, 2322-2328	6	19

71	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 857-865	4.2	1
70	Increased abundance is associated with clinical improvement in patients receiving rifaximin treatment. *Beneficial Microbes*, **2020**, 11, 519-525	4.9	4
69	Beyond the HLA Genes in Gluten-Related Disorders. *Frontiers in Nutrition*, **2020**, 7, 575844	6.2	9
68	COVID-19 and intestinal inflammation: Role of fecal calprotectin. *Digestive and Liver Disease*, **2020**, 52, 1231-1233	3.3	20
67	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. *Inflammatory Bowel Diseases*, **2020**, 26, 1306-1314	4.5	22
66	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. *Microorganisms*, **2020**, 8,	4.9	11
65	Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment. *European Journal of Gastroenterology and Hepatology*, **2020**, 32, 1527-1532	2.2	3
64	Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: a multidisciplinary management experience. *European Review for Medical and Pharmacological Sciences*, **2020**, 24, 564-570	2.9	2
63	A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors. *European Review for Medical and Pharmacological Sciences*, **2020**, 24, 8469-8476	2.9	
62	Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. *Nutrients*, **2019**, 11,	6.7	20
61	OP29 ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer. *Journal of Crohn's and Colitis*, **2019**, 13, S021-S022	1.5	
60	P497 IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S360-S361	1.5	
59	Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. *Nutrients*, **2019**, 11,	6.7	171
58	Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities. *European Review for Medical and Pharmacological Sciences*, **2019**, 23, 795-810	2.9	25
57	Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. *European Review for Medical and Pharmacological Sciences*, **2019**, 23, 8075-8083	2.9	42
56	Anti-tumor necrosis factor therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. *World Journal of Gastroenterology*, **2019**, 25, 1465-1477	5.6	7
55	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. *Gut*, **2019**, 68, 2111-2121	19.2	169
54	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI - San Marino" study. *Digestive and Liver Disease*, **2019**, 51, 218-225	3.3	5

53	Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	47
52	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. *Computers in Biology and Medicine*, **2019**, 104, 335-338	7	0
51	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. *Digestive and Liver Disease*, **2018**, 50, 421-428	3.3	158
50	Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals. *Digestive and Liver Disease*, **2018**, 50, 635-639	3.3	62
49	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. *Digestive Diseases*, **2018**, 36, 56-65	3.2	85
48	European Crohn□s and Colitis Organisation Topical Review on Treatment Withdrawal [□Exit Strategies□] in Inflammatory Bowel Disease. *Journal of Crohn□s and Colitis*, **2018**, 12, 17-31	1.5	83
47	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-□on the Liver. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	35
46	Considering gut microbiota disturbance in the management of Helicobacter pylori infection. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 899-906	4.2	8
45	Gut Microbiota Profiling and Gut-Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *Frontiers in Microbiology*, **2018**, 9, 675	5.7	51
44	The Use of Probiotics in Different Phases of Diverticular Disease. *Reviews on Recent Clinical Trials*, **2018**, 13, 89-96	1.2	15
43	for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients*, **2018**, 10,	6.7	34
42	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn□s disease. *Expert Opinion on Investigational Drugs*, **2018**, 27, 543-551	5.9	9
41	Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. *Minerva Gastroenterologica E Dietologica*, **2018**, 64, 351-362	1.6	34
40	Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohn□s Disease. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	8
39	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. *Alcoholism: Clinical and Experimental Research*, **2018**, 42, 2313-2325	3.7	16
38	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E9362-E9370	11.5	62
37	Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel. *Inflammatory Bowel Diseases*, **2018**, 24, 2198-2210	4.5	16
36	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 152-159	6.1	79

35	A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis. *PLoS ONE*, **2017**, 12, e0174121	3.7	6
34	Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis. *Inflammatory Bowel Diseases*, **2017**, 23, 392-403	4.5	13
33	Can We Predict the Efficacy of Anti-TNF-Agents?. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	43
32	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	32
31	Proteobacteria: A Common Factor in Human Diseases. *BioMed Research International*, **2017**, 2017, 9351507	3	342
30	Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. *Gastroenterology Research and Practice*, **2017**, 2017, 8646495	2	73
29	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. *PLoS ONE*, **2017**, 12, e0186575	3.7	13
28	Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea. *European Review for Medical and Pharmacological Sciences*, **2017**, 21, 873-883	2.9	12
27	Bacillus clausii and gut homeostasis: state of the art and future perspectives. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 943-8	4.2	16
26	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. *Digestive and Liver Disease*, **2016**, 48, 391-8	3.3	13
25	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. *World Journal of Gastroenterology*, **2016**, 22, 9727-9733	5.6	3
24	Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?. *World Journal of Gastroenterology*, **2016**, 22, 10198-10209	5.6	8
23	Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. *World Journal of Gastroenterology*, **2016**, 22, 5505-11	5.6	91
22	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. *Digestive Diseases*, **2016**, 34, 269-78	3.2	72
21	Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease. *Digestive Diseases*, **2016**, 34, 202-9	3.2	14
20	Gut Virome and Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2016**, 22, 1708-12	4.5	30
19	Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. *Expert Opinion on Drug Safety*, **2016**, 15, 983-91	4.1	13
18	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. *Transplantation Proceedings*, **2016**, 48, 402-7	1.1	22

17	High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. *European Review for Medical and Pharmacological Sciences*, **2016**, 20, 297-300	2.9	4
16	Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries. *European Review for Medical and Pharmacological Sciences*, **2016**, 20, 3891-3901	2.9	1
15	Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin. *Mini-Reviews in Medicinal Chemistry*, **2015**, 16, 179-85	3.2	17
14	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. *World Journal of Gastroenterology*, **2015**, 21, 12322-33	5.6	47
13	The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. *European Review for Medical and Pharmacological Sciences*, **2015**, 19, 1068-76	2.9	59
12	The gastrointestinal microbiome - functional interference between stomach and intestine. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2014**, 28, 995-1002	2.5	30
11	Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for gut barrier protectors in IBD?. *United European Gastroenterology Journal*, **2014**, 2, 113-22	5.3	21
10	Anti-TNF-induced psoriasiform lesions in IBD: an abnormal immune activation or a patchy cutaneous immune suppression?. *Gut*, **2014**, 63, 699-701	19.2	2
9	Role of microbiota and innate immunity in recurrent Clostridium difficile infection. *Journal of Immunology Research*, **2014**, 2014, 462740	4.5	31
8	Role of yeasts in healthy and impaired gut microbiota: the gut mycome. *Current Pharmaceutical Design*, **2014**, 20, 4565-9	3.3	32
7	Commensal Clostridia: leading players in the maintenance of gut homeostasis. *Gut Pathogens*, **2013**, 5, 23	5.4	412
6	Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. *Digestive and Liver Disease*, **2013**, 45, 1017-21	3.3	29
5	Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. *Frontiers in Immunology*, **2013**, 4, 181	8.4	86
4	Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. *BioMed Research International*, **2013**, 2013, 435268	3	116
3	Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system. *Journal of Visualized Experiments*, **2013**, e50843	1.6	27
2	Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. *Fibrogenesis and Tissue Repair*, **2012**, 5, 18		59
1	The gut barrier: new acquisitions and therapeutic approaches. *Journal of Clinical Gastroenterology*, **2012**, 46 Suppl, S12-7	3	132